Jefferies Financial Group Reiterates “Hold” Rating for Hims & Hers Health (NYSE:HIMS)

Jefferies Financial Group reiterated their hold rating on shares of Hims & Hers Health (NYSE:HIMS) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $15.00 price objective on the stock, down from their prior price objective of $17.00.

A number of other equities research analysts have also issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a buy rating and a $20.00 price target on the stock. Truist Financial upped their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a research note on Tuesday, February 27th. Tigress Financial upped their price objective on shares of Hims & Hers Health from $14.00 to $15.00 and gave the company a buy rating in a research note on Friday, January 5th. Leerink Partnrs reiterated a market perform rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Finally, Piper Sandler upped their price objective on shares of Hims & Hers Health from $9.00 to $11.00 and gave the company a neutral rating in a research note on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of Moderate Buy and an average price target of $14.85.

Hims & Hers Health Stock Performance

HIMS stock opened at $11.90 on Tuesday. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16. The company’s 50 day simple moving average is $13.51 and its 200-day simple moving average is $9.84.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. The firm’s revenue was up 47.4% compared to the same quarter last year. On average, research analysts anticipate that Hims & Hers Health will post 0.1 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 127,688 shares of the stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $9.08, for a total transaction of $1,159,407.04. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at approximately $469,009.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Soleil Boughton sold 22,839 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17. Following the completion of the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 127,688 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $9.08, for a total transaction of $1,159,407.04. Following the sale, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at $469,009.24. The disclosure for this sale can be found here. Insiders have sold a total of 675,838 shares of company stock worth $8,487,125 in the last 90 days. 31.63% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Several large investors have recently modified their holdings of the company. Belpointe Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after buying an additional 1,205 shares during the period. Principal Financial Group Inc. boosted its holdings in Hims & Hers Health by 9.6% in the 4th quarter. Principal Financial Group Inc. now owns 14,130 shares of the company’s stock valued at $126,000 after purchasing an additional 1,234 shares during the period. Osaic Holdings Inc. boosted its holdings in Hims & Hers Health by 29.1% in the 2nd quarter. Osaic Holdings Inc. now owns 6,213 shares of the company’s stock valued at $58,000 after purchasing an additional 1,400 shares during the period. Virtu Financial LLC boosted its holdings in Hims & Hers Health by 8.4% in the 4th quarter. Virtu Financial LLC now owns 18,441 shares of the company’s stock valued at $118,000 after purchasing an additional 1,430 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Hims & Hers Health by 5.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock valued at $261,000 after purchasing an additional 1,561 shares during the period. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.